Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN1400 · 1 trial · 1 indication
Safety will be assessed through analysis of laboratory data, physical examination findings and vital signs according to the schedule of assessments, in addition to the spontaneous reporting of adverse events according to CTCAE version 4.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Cohort 2 | EXPERIMENTAL | Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Cohort 3 | EXPERIMENTAL | Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Name | Type | Description |
|---|---|---|
| REGN1400 | DRUG | - |
| Erlotinib | DRUG | - |
| Cetuximab | DRUG | - |
Inclusion Criteria include, but are not limited to, the following: 1. Confirmed diagnosis of certain unresectable or metastatic cancers 2. Adequate Eastern Cooperative Oncology Group (ECOG) performance status 3. Adequate hepatic, renal and bone marrow function 4. Resolution of toxicity from prior t...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
REGN1400 is an investigational small molecule being developed by Regeneron Pharmaceuticals for the treatment of cancer. It is an oncology candidate that has been studied in a Phase 1 clinical trial, both as a single agent and in combination with other cancer therapies. It is not an approved medicine.
REGN1400 targets ErbB3, a protein receptor. By binding to ErbB3, the small molecule is designed to interfere with signaling through this receptor, which is part of the ErbB family of growth factor receptors implicated in cancer cell growth and survival.
REGN1400 is developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor of the clinical program studying this small molecule oncology candidate.
REGN1400 is in Phase 1 development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program has been completed, with one registered trial that enrolled 56 patients.
REGN1400 has been studied in one Phase 1 trial, NCT01727869, titled a study of REGN1400 alone and in combination with erlotinib or cetuximab in patients with certain types of cancer. That trial is completed, enrolled 56 patients in the United States, and included adults 18 years and older.
REGN1400 was studied in patients with certain types of cancer. The Phase 1 trial evaluated the drug both as a single agent and in combination with erlotinib or cetuximab. It remains an investigational therapy and is not approved for any cancer indication.